Ceftriaxone is obviously not a popular choice for MSSA bacteremia among #IDtwitter
There is no prospective data showing it's inferior to other options so far
So why?
What I’m good at:
- hyponatremia
- pneumonia
- sepsis
- heart failure
What my family asks me about:
- ear itch
- boob pain
- random rashes
- “am I farting too much?”
Our prospective Paxlovid rebound study with controls preprint is posted
By symptoms: ~12% rebound (19% Pax vs 7% controls)
By positive testing: ~5% rebound (14% Pax vs 9% controls)
Much lower than many estimates
https://t.co/czeGEYIJvA by @JayPandit@michaelmina_lab@ScrippsRTI
Is dalbavacin, a potent bactericidal, long acting lipoglycopeptide, truly the answer for improved all-cause mortality and reduced recurrences for MRSA infections compared to standard of care treatment? Tune in to the next ACCP ID PRN Learner-led JC Club session on November 18th!
What a helpful summary for those of us who could not join! These topics are incredibly relevant, I look forward to hearing more about what you learned tomorrow during stewardship rounds!